WO2004073590A3 - Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies a la prostaglandine f2-$g(a) du recepteur de la proteine g - Google Patents
Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies a la prostaglandine f2-$g(a) du recepteur de la proteine g Download PDFInfo
- Publication number
- WO2004073590A3 WO2004073590A3 PCT/EP2004/001200 EP2004001200W WO2004073590A3 WO 2004073590 A3 WO2004073590 A3 WO 2004073590A3 EP 2004001200 W EP2004001200 W EP 2004001200W WO 2004073590 A3 WO2004073590 A3 WO 2004073590A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- alpha
- prostaglandin
- therapeutics
- diagnostics
- Prior art date
Links
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 title abstract 4
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 title abstract 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000012931 Urologic disease Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002124 endocrine Effects 0.000 abstract 2
- 208000014951 hematologic disease Diseases 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention a trait à la prostaglandine F2-α du récepteur couplé à la protéine G liée à des pathologies cardio-vasculaires, urologiques, hématologiques, endocriniennes, gastro-entérologiques, à des affections du métabolisme, respiratoires et au cancer. Elle porte également sur des dosages permettant de recenser des composés des plus utiles en matière de traitement ou de prévention de pathologies cardio-vasculaires, urologiques, hématologiques, endocriniennes, dermatologiques, gastro-entérologiques, d'affections du métabolisme, d'affections respiratoires et du cancer. Elle concerne, en outre, des composés se liant à la prostaglandine F2-α et/ou activant ou inhibant l'action de celle-ci ainsi que des compositions pharmaceutiques contenant ces composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03003249.4 | 2003-02-24 | ||
| EP03003249 | 2003-02-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004073590A2 WO2004073590A2 (fr) | 2004-09-02 |
| WO2004073590A3 true WO2004073590A3 (fr) | 2005-06-02 |
Family
ID=32892848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/001200 WO2004073590A2 (fr) | 2003-02-24 | 2004-02-10 | Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies a la prostaglandine f2-$g(a) du recepteur de la proteine g |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2004073590A2 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869281A (en) * | 1993-06-25 | 1999-02-09 | Merck Frosst Canada Inc. | DNA encoding prostaglandin receptor FP |
-
2004
- 2004-02-10 WO PCT/EP2004/001200 patent/WO2004073590A2/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869281A (en) * | 1993-06-25 | 1999-02-09 | Merck Frosst Canada Inc. | DNA encoding prostaglandin receptor FP |
Non-Patent Citations (5)
| Title |
|---|
| FOGERON M L ET AL: "New differentially expressed stomach cancer markers identified through extended proteomics analysis on highly selected tumor samples.", MOLECULAR AND CELLULAR PROTEOMICS, vol. 1, no. 9, September 2002 (2002-09-01), & FIRST WORLD CONGRESS OF THE HUMAN PROTEOME ORGANISATION; VERSAILLES, PARIS, FRANCE; NOVEMBER 21-24, 2002, pages 674, XP002298594, ISSN: 1535-9476 * |
| FUJINO H ET AL: "Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 7, July 2003 (2003-07-01), pages 335 - 340, XP004438370, ISSN: 0165-6147 * |
| KOBAYASHI TAKUYA ET AL: "Function of prostanoid receptors: studies on knockout mice.", PROSTAGLANDINS & OTHER LIPID MEDIATORS. AUG 2002, vol. 68-69, August 2002 (2002-08-01), pages 557 - 573, XP002298593, ISSN: 1098-8823 * |
| SHARIF N A ET AL: "Bimatoprost (Lumigan(R)) is an agonist at the cloned human ocular FP prostaglandin receptor: Real-time FLIPR-based intracellular Ca2+ mobilization studies.", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 68, no. 1, January 2003 (2003-01-01), pages 27 - 33, XP002298595, ISSN: 0952-3278 * |
| TSAI S -J ET AL: "Regulation of prostaglandin F2alpha and E receptor mRNA by prostaglandin F2alpha in ovine corpora lutea", JOURNAL OF REPRODUCTION AND FERTILITY, vol. 114, no. 1, September 1998 (1998-09-01), pages 69 - 75, XP009032445, ISSN: 0022-4251 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004073590A2 (fr) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006027147A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr) | |
| WO2005093092A3 (fr) | Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44) | |
| WO2005106012A3 (fr) | Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1) | |
| WO2006005469A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr) | |
| WO2005114207A3 (fr) | Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep) | |
| WO2005103684A3 (fr) | Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c | |
| WO2005031345A3 (fr) | Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2) | |
| WO2006021343A3 (fr) | Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a) | |
| WO2004073590A3 (fr) | Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies a la prostaglandine f2-$g(a) du recepteur de la proteine g | |
| WO2005076007A3 (fr) | Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) | |
| WO2004073589A3 (fr) | Diagnostics et therapies de maladies associees au recepteur de la prostaglandine e2 ep4 (prostaglandine e2 ep4) lie a la proteine g | |
| WO2005073729A3 (fr) | Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11) | |
| WO2005093091A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26) | |
| WO2005095953A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 6 (ccr6) | |
| WO2004074830A3 (fr) | Diagnostics et therapies de maladies associees au recepteur de la prostaglandine e2 ep3 iii (prostaglandine e2 ep3 iii) lie a la proteine g | |
| WO2005090994A3 (fr) | Diagnostic et therapeutique pour des maladies associees a la proteine kinase, dependante de cgmp, type 1 (prkg1) | |
| WO2005113786A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1) | |
| WO2005119263A3 (fr) | Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92) | |
| WO2005040791A3 (fr) | Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr) | |
| WO2004074842A3 (fr) | Diagnostics et therapies de maladies associees au recepteur de la prostaglandine e2 ep3 (prostaglandine e2 ep3) lie a la proteine g | |
| WO2005075983A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3) | |
| WO2006005461A3 (fr) | Diagnostic et traitement des maladies associees au recepteur 27 couple aux proteines g (rcpg 27) | |
| WO2004073591A3 (fr) | Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies a la prostaglandine e2 ep2 du recepteur de la proteine g | |
| WO2004075814A3 (fr) | Produits diagnostiques et therapeutiques pour des maladies associees a la prostaglandine e2 ep3 i recepteur couple a la proteine g | |
| WO2005093426A3 (fr) | Diagnostics et therapeutiques pour des maladies associees au recepteur d'acide retinoique alpha (rara) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |